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Abstract 
  BACKGROUND: There is a lack of data in our society on the outcomes, complications, and 
prognostic factors in patients with coronary artery disease who underwent percutaneous 
coronary intervention (PCI). We evaluated the success rate, early and late outcomes, and 
prognostic factors in a referral university center in Isfahan, IRAN. 
 METHODS:  This prospective cohort study was conducted in Chamran University Hospital in 
Isfahan (IRAN) from March 2010 to February 2011. Patients consequently were included if they 
have the indication for emergent or elective PCI. Outcomes included procedural success, 
complications, and major adverse cardiovascular events (MACE) during hospitalization and 6 
months follow-up. 
 RESULTS: A total of 282 patients (74.1% females) with mean age of 57.0±3.2 years were 
studied. Most of the patients (89.7%) underwent elective PCI. Angiographic and procedure 
success rates were 95.7% and 94.6%, respectively. In-hospital MACE included two cases of death 
(0.7%) and one MI (0.3%); 2/29 (6.9%) of the emergent PCI and 1/253 (0.4%) of the elective 
PCI cases. MACE during follow-up included three cases of death (1.0%) and two MI (0.7%); 
2/252 (0.8%) of the elective PCI and 1/28 (3.5%) of the emergent PCI cases. The overall MACE 
was calculated as 8 cases (2.8%) which included 5/29 (17.2%) of the emergent and 3/253 (1.1%) 
of the elective cases; P < 0.001. In multivariate analysis, none of the factors including gender, 
age, emergency of the procedure, lesion type, number of stenotic vessels, or stent type were 
associated with total MACE (P > 0.05). 
  CONCLUSION: PCI is performed with an acceptable success rate in our center in Isfahan and 
mortality and complications are within the range reported by other highly specialized centers in 
IRAN. Further studies with larger sample size are needed to find predictive factors. 
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Introduction 
Despite considerable ongoing improvements in 
preventive programs and access to the specialized 
medical care, atherosclerosis and its complications 
such as acute myocardial infarction (MI) are still 
regarded as the most important causes of death in 
developed as well as developing societies.1,2 In Iran, 
coronary artery diseases (CAD) are yet the leading 
causes of death with up to 40% of all causes of death 
and also one of the leading causes of disability and 
morbidity.3,4
 
Since its development, reperfusion therapy has 
been a great improvement in the treatment of MI and 
significantly decreased the associated mortality and 
morbidity. Medical therapies (fibrinolytic agents) and 
surgical interventions (percutaneous coronary 
intervention (PCI) and coronary artery bypass surgery 
(CABG)) are available for the treatment of CAD 
patients. Patients with typical chest pain and 
electrocardiographic (ECG) evidence of an acute MI 
are candidates for either PCI or fibrinolytic therapy.5 
Coronary reperfusion with primary PCI or fibrinolytic 
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therapy improves outcomes in patients with acute ST-
segment elevation MI (STEMI) and if it was timely 
performed, primary PCI is the reperfusion therapy of 
choice compared to fibrinolysis, because it achieves 
significantly better outcomes and does not carry the 
risks that are associated with fibrinolytic therapy (e.g. 
intracranial hemorrhage).6,7 Although evidence 
showed that, compared with PCI under stable angina 
and elective conditions, emergent PCI for patients 
with unstable angina has been associated with a 
slightly lower success rate and higher peri-
procedural/in-hospital complications and higher re-
stenosis, it is a widely administered treatment strategy 
for patients with non ST-segment elevation MI 
(NSEMI), as well.8-10  
Several factors can affect the reperfusion therapy 
of choice. Besides characteristics such as patient age 
and general condition, kind and degree of the 
stenosis, patient and system delays, emergency of the 
condition, and patient preferences, specialized care 
facilities and high costs of the invasive procedures are 
also important.11-13 It is of great importance for an 
interventionist to recognize the main predictors of 
such an invasive intervention outcomes and 
complications to efficiently decide about the 
treatment strategy. Although, several centers have 
described their experience with primary PCI during 
these years, concern persists as to whether the results 
of highly specialized centers could be generalized to 
clinical practice. There are some few published data 
on the outcomes, complications, and prognostic 
factors from centers in our society.14-22 According to 
reports from Tehran Heart Center, success rate is up 
to 98%, mortality rate (including one year follow-up) 
from about 0.3% to 8.5%, and major complications 
from 1.6% to 19.2%.14-17,20,21 Regarding the lack of 
data from our society in this regard, the object of this 
study was to determine the success rate of PCI, early 
and late outcomes, and prognostic factors in a referral 
university center in Isfahan, IRAN. 
Materials and Methods 
Patients and settings 
This prospective cohort study was conducted in 
Chamran University Hospital in Isfahan (IRAN) from 
March 2010 to February 2011. Patients were included 
consequently if they have the indication for emergent 
or elective PCI; STEMI, NSTEMI, and unstable 
angina (UA). STEMI was defined as cases that referred 
within 12 hours from the symptom onset with a typical 
chest pain (lasting for more than 30 minutes) and have 
concomitant ECG changes; ST-segment elevation of 
≥1 mm in at least two consecutive precordial/inferior 
leads or the presence of a left bundle branch block. 
Confirmation of MI was done according the elevation 
of cardiac enzymes of more than twice the normal of 
the upper range. UA was defined by the sudden 
appearance/worsening of angina, with more frequent 
and prolonged attacks occurring at rest or on efforts 
that were previously well tolerated. The ethics 
committee of Isfahan University of Medical Sciences 
approved the study and informed consent was 
obtained from the patients or relatives. 
 
Angiographic characteristics, PCI procedures, 
and related care 
Lesion morphology was classified according to the 
modified American Heart Association/ American 
College of Cardiology (AHA/ACC) classification 
taskforce. Reference vessel diameter, degree of 
stenosis, and lesion lengths were estimated visually, 
referencing the catheter or by aid of the device 
software. PCI procedures, technical details, and 
choice of stent were left to the operators’ judgment. 
Unfractionated heparin (70-100 u/kg) was 
administered before guide-wire insertion to achieve a 
clotting time > 250 sec. All the patients were 
pretreated with clopidogrel (600 mg) and ASA (325 
mg). A loading dose of 600 mg of clopidogrel was 
administered if the patient was not pretreated. 
Patients with acute MI and those with thrombosis in 
angiography received (/intravenous) glycoprotein 
IIb/IIIa receptor inhibitor during the procedure, as 
well. After the procedure, aspirin (325 mg/d) was 
continued for 1 months and then 80 mg/d 
indefinitely. Clopidogrel (75 mg/d) was administered 
for a period of 2 months after bare metal stent (BMS) 
implantation and 12 months in patient with ACS or 
after implantationof drug-eluting stent (DES), 
respectively. In patients without contraindications, 
beta-blockers, angiotensin-converting enzyme 
inhibitors, and stains were also administered. For all 
the patients, 12-lead electrocardiography was obtained 
prior and following intervention to detect procedure-
related ischemic changes and or the appearance of a 
new pathologic Q wave on the surface 
electrocardiogram. After the procedure, all the 
patients were checked for creatine kinase MB (CK-
MB) enzyme sampling at 8 and 16 hours.  
 
Assessments 
General characteristics included age, gender, and 
patients medical history including the following risk 
factors: smoking history; current smoker defined as 
patient who regularly smokes one or more times per 
day or has smoked in the 30 days prior to admission 
or quitted smoker defined as those who quitted 
smoking since 30 days before hospitalization, 
dyslipidemia; total cholesterol ≥ 200 mg/dL, HDL-
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cholesterol  ≤ 35 mg/dL, LDL-cholesterol ≥ 100 
mg/dL, and/or triglycerides ≥ 200 mg/dL, 
hypertension; systolic blood pressure ≥140 mmHg 
and/or diastolic ≥90 mmHg and/or on anti-
hypertensive treatment, and known diabetes mellitus. 
 
Outcome  
TIMI flow of the infarct-related arteries was 
determined before and after PCI. Angiographic 
success was defined as a TIMI-3 and < 20% residual 
stenosis and procedural success was defined as the 
angiographic success without major procedural or in-
hospital complications (death, MI, emergent surgery, 
or repeated PCI). The no-reflow phenomenon was 
defined as TIMI < 3 after PCI in spite of residual 
stenosis <50%, absence of significant dissection, or 
visible thrombosis or spasm. 
Major adverse cardiovascular events (MACE): in-
hospital and six-month rates of death, MI, target 
vessel revascularization (TVR), and target lesion 
revascularization (TLR). Death was defined as 
mortality from any cause. Peri-procedural MI was 
defined by a rise in the CK-MB fraction of more than 
5 times the upper limit of normal. TVR and TLR 
were defined as the revascularization of the vessel and 
target lesion, respectively, formerly treated by PCI 
during the index hospitalization by a repeat PCI or 
bypass surgery within 24 hours after the index PCI. 
 
Follow-up 
Each patient was followed-up for 6 months after the 
index procedure. Data of the early outcomes and 
occurrence of death, new MI, need for CABG, 
subsequent need for repeat PCI, and occurrence of 
angina were obtained by office visits or telephone 
interviews. Angiographic follow-up and repeat 
revascularization was only performed if clinically 
indicated by symptoms or documentation of 
myocardial ischemia in non-invasive tests. 
 
Statistical analyses 
Continuous variables are expressed as mean±SD, and 
dichotomous variables as frequencies. Categorical 
variables were compared using the chi-square test and 
continuous variables by using student t test. 
Univariate and multivariate logistic regression analyses 
were performed to identify the independent 
predictors of outcomes (showed in logistic regression 
tables). The odds ratio (OR) and its 95% confidence 
interval (CI) were computed for the outcome 
measures. A p value of less than 0.05 was considered 
statistically significant. The statistical analyses were 
performed with SPSS 16.0 software (SPSS Inc. 
Chicago, IL). 
Results 
The study population consisted of 73 males and 209 
females with the mean age of 57.0±3.2. According to 
medical history, risk factors included hypertension 
(34.0%), dyslipidemia (28.0%), and DM (20.2%). 
Also, 19.8% of the patients were current smokers and 
6.0% were quitted smokers.  
 
Angiographic and lesion characteristics 
Angiographic and lesion characteristics of the patients 
are presented in table 1. Most of the patients (89.7%) 
underwent elective PCI.  
 
Table 1: Angiographic and lesion characteristics 
  N = 282 
Indication of PCI
Emergent, n = 29 (10.2%) 
1- STEMI/rescue 5 (2.2%) 
2- STEMI/Primary 10 (4.3%) 
5- UA 14 (6.1%) 
Elective 253 (89.7%) 
Direct/Secondary Stenting 121 (42.9%) / 161 (57.0%) 
DES/Non-DES, n = 265 164 (58.1%) / 118 (41.8%) 
RVD (mm) 2.36 ± 18.8 [SE = 1.1] 
Lesion length (mm) 16.5 ± 11.5 [SE = 0.6] 
Number of stenotic vessels
SVD 140  (49.6%) 
2VD 105  (37.2%) 
3VD 27  (9.6%) 
MVD 10  (3.5%) 
Lesion Characteristics
A 29  (10.3%) 
B1 108  (38.3%) 
B2 48  (17.0%) 
C 97  (34.4%) 
Data are presented as mean±SD or number (%)
SVD = single vessel disease MVD = multi vessel disease 
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Procedural and early outcomes 
Data regarding procedural characteristics and 
outcomes are presented in table 2. Angiographic and 
procedure success rates were 95.7% and 94.6%, 
respectively. Procedural related complications 
included dissection (3.5%), side branch occlusion 
(0.3%), and abrupt Closure (0.7%). In-hospital events 
and complications were two death (0.7%) including 
one case with emergent PCI (1/29, 3.4%) and one 
with elective PCI (1/253, 0.4%), one MI (0.3%), one 
cerebro-vascular attack (CVA) (0.3%), and one 
ventricular arrhythmia (0.3%). No one needed 
emergent surgical intervention. In overall, 3/282 (1%) 
of the cases experienced a major adverse cardiac 
event during hospitalization which included 2/29 
(6.9%) of the emergent PCI and 1/253 (0.4%) of the 
elective PCI cases; P = 0.029. 
 
Follow-up and late outcomes 
Three patients (1.0%) died during follow-up; two of  
 
the elective PCI (2/252, 0.8%) and one of the 
emergent PCI cases (1/28, 3.5%), and two patients 
(emergent PCI cases) experienced MI (0.7%). MACE 
was therefore calculated as 1.7% (5/280) in all cases 
during follow-up. This included 3/252 (1.2%) of the 
elective PCI and 2/28 (7.1%) of the emergent PCI 
cases; P = 0.8. With regards to MACE during 
hospitalization, the overall MACE was calculated as 8 
cases (2.8%) which included 5/29 (17.2%) of the 
emergent and 3/253 (1.1%) of the elective cases;   
P < 0.001. 
 
Multivariate analysis 
The logistic regression analysis was carried out 
considering all factors which might have an effect in 
MACE. The results showed that none of the factors 
including gender, age, emergency of the procedure, 
lesion type, number of stenotic vessels, or stent type 
were associated with total MACE (P > 0.05). (showed 
in logistic regression tables). 
 
 
Table 2. Procedural and early outcomes 
  N = 282 
Preprocedural stenosis (%)  80.7 ± 29.3 [SE = 1.7] 
Post procedural stenosis (%)  2.5 ± 8.0 [SE = 0.4] 
Angiographic success  270 (95.7%) 
Procedural success  267 (94.6%) 
In-hospital Complications 
Death 2  (0.7%) 
MI 1  (0.3%) 
Emergent CABG  0 
CVA 1  (0.3%) 
Arrhythmia 1  (0.3%) 
Any In-Hospital MACE  3 (1.0%) 
MACE = major adverse cardiac event       CABG = coronary arthery bypass graft 
 
 
Table 3. Follow-up and late outcomes 
 N  =  280 
Death 3  (1.0%) 
MI 2  (0.7%) 
TVR/TLR 0 
Repeated PCI/CABG  0 
Any MACE at Follow  5 (1.7%) 
Any MACE total  8 (2.8%) 
MACE = major adverse cardiac event   TVR = target vessel revascularization                                                
TLR = target lesion revascularization 
T 
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Discussion 
The purpose of the present study was to assess the 
early and late outcomes of patients with CAD after 
reperfusion therapy with PCI in a single university-
affiliated tertiary medical center in Isfahan (IRAN), 
and compare it with the results reported from other 
centers in our country as well as other countries. We 
achieved an acceptable angiographic and procedural 
success rates of 95.7% and 94.6%, respectively, while 
the success rate reported from other centers in Iran 
and also other highly specialized centers is between 
90% to 99%.14-17,20,21,23 The variation between these 
reports can be related to the improving success 
overtime, differences in experience, different patient 
population, and differences in definition of 
procedural success. According to our study results, 
1% of the patients experienced a major adverse 
cardiac event during hospitalization and 1.7% during 
6-month follow-up; leading to a total MACE of 2.8%. 
This included total mortality rate of 6.9% in emergent 
and 1.2% in elective PCI cases. Available reports 
from Tehran Heart Center shows a mortality rate 
from about 0.3% to 8.5% and major complications 
from 1.6% to 19.2%.14-17, 20, 21 Among the reports with 
large sample size, is the study by Alidoosti and 
colleagues on 1311 consecutive patients from 2003 to 
2007 in Tehran Heart Center who underwent elective 
PCI using sirolimus/paclitaxel-eluting stents. Authors 
reported 0.15% in-hospital mortality and 0.76% total 
mortality rate and a total of 4.2% MACE. The only 
reported predictive factors in this study was the 
reference vessel diameter.18 In another report from 
Alidoosti and colleagues from the same center, 
authors found that patients left ventricular 
dysfunction, as measured by ejection fraction, had 
higher rates of MACE and mortality.20 In large series 
from experienced centers, mortality rate is ranged 
from 0.5% to 1.7%24 and according to a report from 
the American College of Cardiology National 
Cardiovascular Data registry which included over 
100,000 PCI procedures (between 1998 and 2000) the 
mortality rate was 1.4%.25 The mortality rate in our 
patients with emergent PCI was 6.9%, higher than 
that of the elective PCI cases. Alidoosti and 
colleagues in a report of 83 patients with STEMI who 
underwent PCI between 2003 to 2005, found a 8.5% 
mortality rate.21 Some evidence showed that mortality 
rate as well as complications are relatively more 
frequent in patients undergoing emergent PCI 
compared with elective PCI.26 However, there are 
controversial results in this regard.27 In our study, 
while MACE was significantly more prevalent in 
those who underwent emergent PCI, compared with 
elective PCI, multivariate analysis did not find an 
association which is probably due to the small sample 
size. 
Several other factors are associated with mortality 
and complications during hospitalization and follow-
up of patients who underwent reperfusion therapy 
with PCI. The time to the onset of reperfusion 
therapy is a critical determinant of outcome with both 
PCI and medical reperfusion therapies. Delay in 
reperfusion therapy can be divided into treatment 
delay (time between symptom onset and PCI), door-
to-balloon time (DTB, time from hospital arrival to 
PCI), and patients delay (time from first contact with 
the healthcare system). In one study by Safi and 
colleagues in Tehran on patients who underwent 
primary PCI, authors found a significant association 
between DTB time and mortality rate; 67% in 
patients with DTB > 120 min vs. 4.6% in patients 
with DBT < 120 min.16 While patient delay is not 
easily correctable by the healthcare system, strategies 
to shorten other delays are modifiable and can lead to 
a significant decrease in mortality and morbidity 
rates.28 Another factors predicting the outcomes 
includes hospital performance (hospital and operator 
volume) and local expertise. Studies showed that the 
mortality rate after primary PCI is significantly lower 
in high-volume compared to lower-volume 
hospitals29,30 and an inverse correlation exists between 
in-hospital MACE and operator volume quintile.31,32 
With regard to our center (Chamran Hospital) it must 
be noted that the center is located relatively far from 
the city center which increases delay of therapy, 
especially when patients with emergent condition are 
referred from other centers. However, it is the only 
university-affiliated referral center in the city with 
appropriate facilities (e.g. on-site surgery) for 
performing PCI. Other prognostic factors are 
angiographic characteristics and the kind of stent 
used. Suboptimal reperfusion, post-PCI TIMI flow 
grade, is an important determinant of prognosis after 
PCI. Lack of attainment of TIMI 3 flow is a 
significant independent predictor of mortality 
(adjusted hazard ratio 3.8, 95% CI 2.5-5.7).33 In our 
study, 8 patients did not achieved TIMI 3 flow, but 
none of them died or experienced other MACE. Also, 
we didn’t find association between lesion type and 
drug eluting versus non-drug eluting stents with 
MACE. It must be noted that the sample size of our 
study was small and precise investigation of predictive 
factors with multivariate analysis was not possible. 
Conclusion 
The results of the present study showed that PCI is   
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performed with an acceptable success rate in our center 
in Isfahan and mortality and complications are within 
the range reported by other highly specialized centers in 
IRAN. We found a trend toward worsened outcomes in 
patients who underwent emergent PCI compared to 
elective cases. However, further studies with larger 
sample size are needed to find predictive factors. 
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